Crossmark

A randomized crossover trial to assess therapeutic efficacy and cost reduction of acid ursodeoxycholic manufactured by the university hospital for the treatment of primary biliary cholangitis

Crossref DOI link: https://doi.org/10.1186/s12876-020-01399-5

Published Online: 2020-08-05

Published Print: 2020-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nakano, Larissa Akeme

Cançado, Eduardo Luiz Rachid

Chaves, Cleuber Esteves

Madeira, Maria Cristina Vaz

Katayose, Jéssica Toshie

Nabeshima, Mariana Akemi

Fossaluza, Victor

Uhrigshardt, Gabriela Guimarães

Liting, Zheng

Pinto, Vanusa Barbosa

Carrilho, Flair José

Ono, Suzane Kioko http://orcid.org/0000-0002-6963-0911
Funding

Funding for this research was provided by:

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (1734244)

Conselho Nacional de Desenvolvimento Científico e Tecnológico (308609/2018-2)
License Information

Text and Data Mining valid from 2020-08-05

Version of Record valid from 2020-08-05
More Information

Article History

Received: 23 August 2019

Accepted: 27 July 2020

First Online: 5 August 2020

Ethics approval and consent to participate

: The ethical approval was obtained from the Research Project Analysis Ethics Committee, Hospital das Clínicas, University of São Paulo School of Medicine prior to the commencement of the study (ID: 1.790.088). All patients provided written informed consent to take part in the clinical trial. The clinical trial information sheath was given to all patients that include the objectives, methodology and purpose of the study using a simple layman terms.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below